Hetty Timmer‐Bosscha

4.3k citations

78 papers · 3.5k indexed · 1 hit paper · h-index 33

Impact in

Oncology top 1%
- Drug Transport and Resistance Mechanisms
- Chemokine receptors and signaling
- Cancer Cells and Metastasis
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism

Papers in

Oncology 47
- Drug Transport and Resistance Mechanisms 15
- HER2/EGFR in Cancer Research 6
- Chemokine receptors and signaling 6
Cancer Research 16
- Cancer, Hypoxia, and Metabolism 6

Co-authors: Elisabeth G.E. de Vries Annemiek Walenkamp Urszula Domańska Wouter B. Nagengast Roeliene C. Kruizinga Coby Meijer N. H. Mulder Nanno H. Mulder
Journals: International Journal of Cancer (9 papers)British Journal of Cancer (7 papers)Cancer Research (6 papers)Journal of Nuclear Medicine (5 papers)European Journal of Cancer (4 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Hetty Timmer‐Bosscha

77 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

A review on CXCR4/CXCL12 axis in oncology: No place to hide 2012 · 510 citations

Peers

Countries citing papers authored by Hetty Timmer‐Bosscha

Since Specialization

Citations

This map shows the geographic impact of Hetty Timmer‐Bosscha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hetty Timmer‐Bosscha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hetty Timmer‐Bosscha more than expected).

Fields of papers citing papers by Hetty Timmer‐Bosscha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hetty Timmer‐Bosscha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hetty Timmer‐Bosscha. The network helps show where Hetty Timmer‐Bosscha may publish in the future.

Co-authors

The 25 scholars most cited alongside Hetty Timmer‐Bosscha, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hetty Timmer‐Bosscha Line = papers co-authored together Hetty Timmer‐Bosscha links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer Breast Cancer Research ·Si-Qi Qiu, Johan van Rooijen, Hilde H. Nienhuis, Bert van der Vegt, Hetty Timmer‐Bosscha, Elise van Leeuwen-Stok, Annemiek Walenkamp, Carolien H. M. van Deurzen, Geertruida H. de Bock, Elisabeth G.E. de Vries, Carolien P. Schröder	2020	6
2	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2–positive breast cancer European Journal of Cancer ·Johan M. van Rooijen, Si-Qi Qiu, Hetty Timmer‐Bosscha, Bert van der Vegt, James E. Boers, Carolien P. Schröder, Elisabeth G.E. de Vries	2018	20
3	Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma Familial Cancer ·Roeliene C. Kruizinga, Denise M.S. van Marion, Wilfred F.A. den Dunnen, Jan Cees de Groot, Eelco W. Hoving, Sjoukje F. Oosting, Hetty Timmer‐Bosscha, R. Derks, Chantal Cornelissen, Rob B. van der Luijt, Thera P. Links, Elisabeth G.E. de Vries, Annemiek Walenkamp	2016	12
4	Microenvironment involved in FPR1 expression by human glioblastomas Journal of Neuro-Oncology ·Jennifer C. Boer, Denise M.S. van Marion, Justin V. Joseph, Nathalie M. Kliphuis, Hetty Timmer‐Bosscha, Jos A. G. van Strijp, Elisabeth G.E. de Vries, Wilfred F.A. den Dunnen, Frank A.E. Kruyt, Annemiek Walenkamp	2015	10
5	Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer European Journal of Cancer ·Anton G.T. Terwisscha van Scheltinga, Paul Berghuis, Hilde H. Nienhuis, Hetty Timmer‐Bosscha, Linda Pot, Sietske B.M. Gaykema, Marjolijn N. Lub–de Hooge, Jos G. W. Kosterink, Elisabeth G.E. de Vries, Carolien P. Schröder	2014	18
6	HER3, serious partner in crime Pharmacology & Therapeutics ·Arjan Kol, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer‐Bosscha, Laetitia E. Lamberts, Frederike Bensch, Elisabeth G.E. de Vries, Carolina P. Schröder	2014	52
7	Targeting breast cancer through its microenvironment: Current status of preclinical and clinical research in finding relevant targets Pharmacology & Therapeutics ·Hilde H. Nienhuis, Sietske B.M. Gaykema, Hetty Timmer‐Bosscha, Mathilde Jalving, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge, Bert van der Vegt, Beth Overmoyer, Elisabeth G.E. de Vries, Carolina P. Schröder	2014	22
8	Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake Cancer Research ·Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting, Anton G.T. Terwisscha van Scheltinga, Jourik A. Gietema, E.T. Garbacik, Hetty Timmer‐Bosscha, Marjolijn N. Lub–de Hooge, Carolina P. Schröder, Elisabeth G.E. de Vries	2013	98
9	Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer Expert Reviews in Molecular Medicine ·Roelof Koster, Marcel A.T.M. van Vugt, Hetty Timmer‐Bosscha, Jourik A. Gietema, Steven de Jong	2013	47
10	Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus British Journal of Cancer ·Jennifer C. Boer, Urszula Domańska, Hetty Timmer‐Bosscha, Ingrid G. J. Boer, Carla J. C. de Haas, Justin V. Joseph, Frank A.E. Kruyt, Elisabeth G.E. de Vries, Wilfred F.A. den Dunnen, Jos A. G. van Strijp, Anna Maria Elisabeth Walenkamp	2013	22
11	Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model Clinical Cancer Research ·Arne R.M. van der Bilt, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer‐Bosscha, Carolien P. Schröder, Linda Pot, Jos G. W. Kosterink, Ate G.J. van der Zee, Marjolijn N. Lub–de Hooge, Steven de Jong, Elisabeth G.E. de Vries, Anna K.L. Reyners	2012	49
12	Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells Journal of Biochemical and Molecular Toxicology ·Margaretha van der Deen, Elisabeth G.E. de Vries, Hylke Visserman, Wouter Zandbergen, Dirkje S. Postma, Wim Timens, Hetty Timmer‐Bosscha	2007	43
13	Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice Respiratory Research ·Margaretha van der Deen, Wim Timens, Hetty Timmer‐Bosscha, Barry WA van der Strate, Rik J. Scheper, Dirkje S. Postma, Elisabeth G.E. de Vries, Huib A.M. Kerstjens	2007	43
14	ATP-binding cassette (ABC) transporters in normal and pathological lung Respiratory Research ·Margaretha van der Deen, Elisabeth G.E. de Vries, Wim Timens, Rik J. Scheper, Hetty Timmer‐Bosscha, Dirkje S. Postma	2005	164
15	Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity Blood ·Dorina M. van der Kolk, Edo Vellenga, Anneke Y. van der Veen, Leonore Noordhoek, Hetty Timmer‐Bosscha, Gert J. Ossenkoppele, Reinier Raymakers, Michael Müller, Eva van den Berg, Elisabeth G.E. de Vries	2000	21
16	Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines International Journal of Cancer ·Marleen Bakker, Johan Renes, Anneke Groenhuijzen, P. Visser, Hetty Timmer‐Bosscha, Michael Müller, Harry J.M. Groen, Egbert F. Smit, Elisabeth G.E. de Vries	1997	24
17	Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin‐resistant tumor cell lines International Journal of Cancer ·Marleen Bakker, Johan Renes, Anneke Groenhuijzen, P. Visser, Hetty Timmer‐Bosscha, Michael Müller, Harry J.M. Groen, Egbert F. Smit, Elisabeth G.E. de Vries	1997	4
18	Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines British Journal of Cancer ·MWJ Sark, Hetty Timmer‐Bosscha, Coby Meijer, DRA Uges, W.J. Sluiter, WHM Peters, NH Mulder, Elisabeth G.E. de Vries	1995	49
19	In vitro response of human small‐cell lung‐cancer cell lines to chemotherapeutic drugs; no correlation with clinical data International Journal of Cancer ·Egbert F. Smit, Elisabeth G.E. de Vries, Hetty Timmer‐Bosscha, L. F. H. M. de Leij, J. Wolter Oosterhuis, R.J. Scheper, J J Weening, Pieter E. Postmus, Nanno H. Mulder	1992	13
20	Combined in vitro modulation of adriamycin resistance International Journal of Cancer ·Coby Meijer, N. H. Mulder, Hetty Timmer‐Bosscha, W. H. M. Petfrs, Elisabeth G.E. de Vries	1991	37

About Hetty Timmer‐Bosscha

Hetty Timmer‐Bosscha is a scholar working on Oncology, Cancer Research, Reproductive Medicine, Molecular Biology and Biochemistry, having authored 78 papers that have together received 3.5k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (15 papers), Cancer therapeutics and mechanisms (9 papers), HER2/EGFR in Cancer Research (6 papers), Cancer, Hypoxia, and Metabolism (6 papers), Chemokine receptors and signaling (6 papers), Immunotherapy and Immune Responses (5 papers), Cancer, Stress, Anesthesia, and Immune Response (4 papers) and Ovarian cancer diagnosis and treatment (4 papers). The work is most often cited by research in Oncology (1.8k citations), Cancer Research (479 citations), Immunology (493 citations), Molecular Biology (1.5k citations) and Radiology, Nuclear Medicine and Imaging (469 citations). Hetty Timmer‐Bosscha has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Elisabeth G.E. de Vries, Annemiek Walenkamp, Urszula Domańska, Wouter B. Nagengast, Roeliene C. Kruizinga, Coby Meijer, N. H. Mulder, Nanno H. Mulder, Gerwin Huls and Steven de Jong. Their work appears in journals such as International Journal of Cancer, British Journal of Cancer, Cancer Research, Journal of Nuclear Medicine and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact